emol, a developer of SaMD for psychiatric disorders, begins exploratory clinical trials of a CBT support app for obsessive-compulsive disorder patients, developed in collaboration with the university

The Department of Neuropsychiatry Hyogo Medical University (Nishinomiya City, Hyogo Prefecture; President: Keiichiro Suzuki) and emol Inc. (Headquarters: Toshima Ward, Tokyo; Representative Director and CEO: Saori Senzu) have jointly developed a medical device program (unapproved, under development) that supports the practice of cognitive behavioral therapy (CBT) through an app for patients with obsessive-compulsive disorder. emol Inc. has now submitted a clinical trial notification (medical device) for an exploratory clinical trial (Phase II clinical trial). The purpose of this clinical trial is to exploratory verify the efficacy and safety of the app, and it will be conducted at three facilities, including Hyogo Medical University Hospital, from June 2025.
For more details, please see the emol Inc. press release here.